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ARTICLE
A fluorogenic cyclic peptide for imaging and
quantification of drug-induced apoptosis
Nicole D. Barth1,7, Ramon Subiros-Funosas1,7, Lorena Mendive-Tapia1, Rodger Duffin1, Mario A. Shields 2,
Jennifer A. Cartwright 1, Sónia Troeira Henriques3,6, Jesus Sot4, Felix M. Goñi4, Rodolfo Lavilla 5,
John A. Marwick1, Sonja Vermeren 1, Adriano G. Rossi1, Mikala Egeblad 2, Ian Dransfield1✉ &
Marc Vendrell 1✉
Programmed cell death or apoptosis is a central biological process that is dysregulated in
many diseases, including inflammatory conditions and cancer. The detection and quantifi-
cation of apoptotic cells in vivo is hampered by the need for fixatives or washing steps for
non-fluorogenic reagents, and by the low levels of free calcium in diseased tissues that
restrict the use of annexins. In this manuscript, we report the rational design of a highly stable
fluorogenic peptide (termed Apo-15) that selectively stains apoptotic cells in vitro and in vivo
in a calcium-independent manner and under wash-free conditions. Furthermore, using a
combination of chemical and biophysical methods, we identify phosphatidylserine as a
molecular target of Apo-15. We demonstrate that Apo-15 can be used for the quantification
and imaging of drug-induced apoptosis in preclinical mouse models, thus creating opportu-
nities for assessing the in vivo efficacy of anti-inflammatory and anti-cancer therapeutics.
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Programmed cell death (apoptosis) is pivotal for main-tenance of tissues and the regulation of inflammatory dis-eases. In contrast to necrosis, plasma membrane integrity is
preserved during apoptosis, preventing the release of intracellular
contents that can damage tissue and trigger inflammatory
responses. Tissue phagocytes recognize apoptotic cells, providing
a mechanism for the safe disposal of apoptotic material. Critically,
excessive apoptosis or failure to clear apoptotic material results in
secondary necrosis with the release of pro-inflammatory intra-
cellular contents. Therefore, the presence of apoptotic cells
represents a biomarker of the extent of tissue injury and corre-
lates to the progression, resolution, and treatment of inflamma-
tory conditions and cancer1,2.
A sequence of morphological and biochemical changes occurs
during apoptosis (e.g., phospholipid exposure, caspase activation,
mitochondrial dysfunction, DNA fragmentation)3–6. Optical
reagents for the detection of these events have been reported, but
many probes alter cellular behavior, limiting their use for non-
invasive detection of apoptosis in vivo. In particular, these lim-
itations impede studies under physiological conditions (e.g.,
intravital imaging) and in situ assessment of therapy-induced
apoptosis in preclinical models. At early stages of apoptosis, the
plasma membrane undergoes profound remodeling and the
activation of the scramblase Xkr8 promotes external exposure of
phospholipids containing phosphatidylserine (PS)-headgroups
and other phospholipids, which are normally restricted to the
intracellular leaflet7. Reagents that bind to PS exposed on the
plasma membrane (e.g., annexins)4,8 have advantages over those
monitoring intracellular changes (e.g., caspase activation, DNA
fragmentation) because they do not require cell permeabilization
or fixation. However, fluorescently-labeled annexins and polarity-
sensitive annexins (pSIVA) require high concentrations of free
Ca2+ (>1 mM) to permit optimal phospholipid binding4,5, lim-
iting their performance in the hypocalcemic regions that are
common in diseased tissues. Furthermore, annexins inhibit the
engulfment of apoptotic cells by phagocytes9, which precludes
quantitative analysis of therapy-induced apoptosis in vivo.
In this study, we describe the rational design, optimization and
validation of a fluorogenic peptide (termed Apo-15) to bind
negatively-charged phospholipids exposed on apoptotic cells.
Apo-15 behaves as a universal apoptosis probe in that it detects
apoptotic cells from multiple origins and in a broad range of
experimental conditions. Furthermore, we demonstrate that Apo-
15 enables fluorescence imaging of apoptosis in vivo and quan-
tification of drug-induced apoptosis in two different preclinical
mouse models of acute lung injury (ALI) and breast cancer.
Results
Rational design and synthesis of fluorogenic peptides. We
designed cyclic amphipathic peptides (termed apopeptides) which
we predicted would bind to phospholipids translocated to the outer
leaflet of apoptotic cell membranes. We focused on small cyclic
peptides because they offer several advantages: (1) resistance to
proteolytic cleavage and oxidative conditions for in vivo studies,
(2) tunability of the properties by changing the amino acid
sequence, which would allow us to optimize binding to apoptotic
cells, (3) compatibility with fluorogenic amino acids for wash-free
imaging, and (4) smaller size than proteins for improved tissue
accessibility. Apopeptides were designed to contain combinations
of polar and hydrophobic amino acids to identify sequences
that would bind to apoptotic cell membranes and remain unable
to bind viable cells. All the apopeptides incorporated the
environmentally-sensitive Trp-BODIPY fluorophore10–12, which
emits bright fluorescence after binding to provide optimal dis-
crimination between viable and apoptotic cells (Fig. 1a, c).
A total of 15 apopeptides were prepared using solid-phase and
solution peptide synthesis (Fig. 1b). In addition to Trp-BODIPY,
apopeptides included tryptophan (W), phenylalanine (F), leucine
(L), valine (V), and isoleucine (I) as hydrophobic residues, and
lysine (K), glutamic acid (E), and arginine (R) as polar residues. In
all cases, one glycine was included at the C-terminal end to facilitate
head-to-tail cyclization (for enhanced resistance to proteolysis13,14),
and to avoid stereoisomeric mixtures. Unprotected amino acids
were used for the hydrophobic residues, whereas protected amino
acids [e.g., Fmoc-Lys(Z)-OH, Fmoc-Glu(Bzl)-OH, Fmoc-Arg
(NO2)-OH] were used for the polar residues. The solid-phase
peptide elongation was performed on 2-chlorotritylchloride poly-
styrene resin using conventional protocols and mild acidic cleavage
conditions [i.e., TFA:DCM (1:99)]15. Peptides were cyclized in a
head-to-tail fashion using COMU as the condensation reagent16,
and side-chain protecting groups were removed to afford all
apopeptides in high purities (>97%) after HPLC purification
(Supplementary Table 1).
The sequences and physicochemical properties of all apopeptides
are summarized in Fig. 1b. We sought to identify those sequences
that would rapidly binding to apoptotic cells with minimal labeling
of viable cells. cLac-BODIPY, a cyclic peptide able to bind apoptotic
bodies but not apoptotic cells11, was included for comparison.
Using a flow cytometry-based assay, we examined the time-
dependent emission of apopeptides in mixtures of both apoptotic
and viable cells. We used human neutrophils cultured in vitro for
18 h, in which a large fraction of the cells (≥50%) undergo tissue
culture-induced apoptosis17. Apoptotic and viable populations were
defined by positive and negative staining with AF647-Annexin V in
media containing 2mM CaCl2, respectively. First, we assessed how
polar residues influenced binding by comparing two peptides with
similar molecular weight and clog P (Supplementary Table 1 and
Fig. 1b), but with either negatively-charged (Apo-0) or positively-
charged (Apo-2) residues. We chose glutamic acid (E) as a
negatively-charged amino acid over aspartic acid to avoid synthetic
complications due to the potential formation of aspartimides18.
Apo-2 showed selective binding to apoptotic cells over viable cells
when compared with Apo-0, indicating the importance of positive
charges for binding to negatively-charged phospholipids on
apoptotic cell membranes. Next, we generated amphipathic peptides
containing positively-charged amino acids and other residues that
would alter binding to apoptotic cell membranes19,20. Specifically,
we synthesized apopeptides to examine the influence of (1)
aromatic vs non-aromatic hydrophobic residues (Apo-3, 4, and
Apo 9–10), (2) alternate vs sequential charges (Apo 5–8), and (3)
overall polarity as determined by clog P values (Apo 11–14).
Temporal analysis indicated that recognition of apoptotic cells
occurred rapidly, with most apopeptides showing ≥80% of full
binding in <4min (Supplementary Table 2). From the screening,
we quantified parameters that defined the selectivity and affinity of
apopeptides: (1) preferential binding to apoptotic vs viable cells as
fluorescence fold increase (Ff), (2) background fluorescence on
viable cells (Bf), and (3) retention of binding upon washing (Rt)
(Fig. 1b). Several apopeptides showed good discrimination between
apoptotic and viable cells (Ff ≥ 10: Apo-2, 3, 6, and 8), negligible
fluorescence on viable cells (Bf ≤ 3: Apo-0, 4, 11, 12, 13, and 14)
and reasonable resistance to washing (Rt ≥ 40%: Apo-2, 3, 6, 8, and
11). Overall, peptide polarity or clog P was related to retention of
labeling (Fig. 1b). Although markedly polar peptides (clog P <−4,
Apo-13 and Apo-14) bound with fast kinetics, their signal was lost
after washing. In contrast, less polar peptides (clog P >−1, Apo-11
and Apo-12) displayed slower binding rates but their binding was
relatively resistant to washing. These analyses suggested that
apopeptides with balanced polarity (clog P between −1 and −4)
exhibited better labeling. Apo-8 presented the highest retention of
signal but also showed the highest binding to viable cells. Our
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–0.68
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Apo-2 KKKWW 18 62
Apo-3 KKKWF 14 47
Apo-4 KKKFF 6 15
Apo-5 KWKWK 7 8
Apo-6 KKWWK 18 40
Apo-7 WWKKK 8 22
Apo-8 KWWKK 13 99
Apo-9 KKKLI <1 n.a.
Apo-10 KKKVI <1 n.a.
Apo-11 KKWWW 7 47
Apo-12 KWWWW <1 n.a.
Apo-13 KKKKW 6 9
Apo-14 KKKKK <1 n.a.
Apo-15 RKKWF 14 42
cLac-BODIPY Reference 11 <1 n.a.
Apo-0 to 15
Fig. 1 Design, synthesis, and in vitro screening of apopeptides. a Synthetic scheme for the preparation of apopeptides (CTC-PS: 2-chlorotritylchloride
polystyrene resin). Stability analysis of Apo-15 (50 μM) under different proteolytic and oxidative environments. b Sequences, physicochemical and binding
properties of apopeptides and cLac-BODIPY. In vitro screening of the peptides (100 nM) was performed by real-time flow cytometry in mixtures of
apoptotic (AF647-Annexin V positive) and viable (AF647-Annexin V negative) neutrophils (n≥ 3, biologically independent experiments). c Fluorescence
activation of apopeptides in apoptotic (right) over viable cells (left), with Trp-BODIPY as the environmentally-sensitive reporter. Pictograms of Apo-15
under 365 nm light excitation. d Representative flow cytometry plots of Apo-0 and Apo-15 binding to mixtures of apoptotic (highlighted in green dots) and
viable cells (highlighted in black dots). Fluorescence emission was recorded for around 4min after addition of apopeptides (100 nM) without washing.
Background fluorescence (Bf) was calculated as the ratio of fluorescence recorded before (x) and 2 min after (y) peptide addition. Fold increase (Ff) in
apoptotic cells was calculated as a ratio of fluorescence recorded for apoptotic cells (y′) to that of viable cells (x′) after 2 min. e Representative
fluorescence confocal microscopy images (from three independent experiments) of viable (white arrows) and apoptotic cells (yellow arrows) after
incubation with Apo-0 (left, green) and Apo-15 (right, green) (both at 100 nM). Cells were co-stained with Hoechst 33342 (7 μM, blue) and AF647-
Annexin V (5 nM, red) as nuclei and apoptosis markers, respectively (λexc.: 405, 488, 633 nm: λem.: 450, 525, 670 nm). Scale bars: 10 μm. Source data
(in b) are provided as a Source data file.
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analyses also revealed the importance of non-electrostatic interac-
tions, with apopeptides lacking hydrophobic aromatic residues
(Apo-9, 10, and 14) exhibiting poor retention of labeling. Besides,
among aromatic amino acids, tryptophan increased specificity
when compared with phenylalanine (Apo-2 vs Apo-4).
Considering all these results, we decided to further optimize the
Apo-3 sequence (Ff: 14; Bf: 4.7; Rt: 47%) to reduce its background
fluorescence on viable cells while retaining full binding to
apoptotic cells. Arginine-rich peptides have been described to
strongly bind molecular targets in other amphipathic sequences,
partially due to the larger polar surface area of arginine compared
with lysine21. Therefore, we synthesized Apo-15 by replacing one
lysine with an arginine residue. Apo-15 [sequence: c(RKKWFW
(BODIPY)G)] displays high selectivity for apoptotic cells (Ff: 14),
marginal background fluorescence on viable cells (Bf: 2.4) and
good retention of signal after three washes with PBS (Rt: 42%).
Representative flow cytometry plots for Apo-0, which does not
bind to apoptotic cells, and Apo-15 are shown in Fig. 1d. We also
examined Apo-0 and Apo-15 for imaging apoptotic cells in the
presence of viable cells (Fig. 1e). Apo-15 displays fluorescence in
the green region of the visible spectrum, being compatible with
conventional GFP and FITC filters (λabs.: 500 nm; λem.: 530 nm;
Supplementary Fig. 1). Notably, Apo-15 displays around 10-fold
brightness (25,000M−1 cm−1) over other environmentally-
sensitive probes for apoptosis [e.g., pSIVA (2500M−1 cm−1), N,
N′-didansyl-L-cystin (3000M−1 cm−1) (Table 1)], which allows
the staining of apoptotic cells at nanomolar concentrations
(30–100 nM, Supplementary Fig. 2). Apo-15 also exhibits high
chemical stability under proteolytic and oxidative conditions.
HPLC analysis confirmed >95% of Apo-15 remained stable after
incubation with a protease cocktail or the oxidizing agent H2O2
(Fig. 1a and Supplementary Figs. 3, 4). Altogether, these properties
made Apo-15 an optimal candidate for further characterization.
Apo-15 delineates apoptotic cells in diverse environments.
Next, we evaluated Apo-15 for the general detection of apoptotic
cells from different species and lineages. We observed that Apo-
15 selectively stained apoptotic cells regardless of their origin.
Specifically, we examined myeloid cells (neutrophils, both human
and mouse, Supplementary Fig. 5), lymphoid cells (BL-2, Burkitt
lymphoma) and primary epithelial cells. We performed these
experiments in the presence of AF647-Annexin V to corroborate
that Apo-15 stains apoptotic and not viable cells. Notably, we
observed very similar staining for Apo-15 and AF647-Annexin V
in media containing 2 mM CaCl2 (Fig. 2a, b). Furthermore, Apo-
15 labeling proved to be independent of the method used to
induce apoptosis [e.g., myeloid: tissue culture-induced apoptosis
by culture at 37 °C for 18 h; lymphoid: irradiation with a CL-1000
Ultraviolet Crosslinker UVP at 254 nm; epithelial: treatment with
staurosporine (1 µM) for 6 h], which highlights the compatibility
of Apo-15 with multiple experimental conditions.
A limitation of annexins is their dependence on high
concentrations of free Ca2+ (>1 mM), which affects their use in
hypocalcemic environments in diseased tissues22. Therefore, we
decided to assess whether Apo-15 was able to delineate apoptotic
cells independently of the concentration of free divalent cations.
Notably, we observed robust binding of Apo-15 to myeloid and
lymphoid apoptotic cells in the presence of the divalent cation
chelator EDTA (2.5 mM), whereas AF647-Annexin V failed to
bind under the same experimental conditions (Fig. 2b–d). Ca2+-
dependent binding to apoptotic cells was also observed for
polarity-sensitive annexins (pSIVA)8 (Supplementary Fig. 6). The
divalent cation-independence of Apo-15 represents a major
advantage over annexins and allows direct monitoring of
apoptosis in most conditions likely to be encountered in vivo. T
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To confirm that cells stained by Apo-15 under divalent cation-
free conditions were apoptotic, we sorted a mixed population of
apoptotic and viable human neutrophils (gating strategy in
Supplementary Fig. 7) according to Apo-15 labeling and examined
their morphology by microscopy. Apo-15-positive neutrophils
exhibited a pyknotic nucleus characteristic of chromatin con-
densation and degradation, together with cell shrinkage, which are
hallmarks of apoptosis (Fig. 2c)23. In contrast, Apo-15-negative
cells showed the typical multilobed nuclear morphology of viable
neutrophils (Fig. 2c). The morphological appearance of Apo-15-
positive cells was examined by scanning electron microscopy.
Apo-15-positive neutrophils showed evidence of apoptosis-
associated blebbing and pitting of the plasma membrane
(Supplementary Fig. 8)24,25. On the other hand, the presence of
microvilli-like structures, which are typical of viable cells, were
observed on the plasma membrane of Apo-15-negative cells
(Supplementary Fig. 8). Apo-15 also discriminated between
different types of cell death by fluorescence lifetime imaging
(FLIM). Human BL-2 cells were induced into apoptosis or
necrosis by differential UV irradiation, incubated with Apo-15
and imaged under a FLIM microscope to reveal that apoptotic and
necrotic cells could be discriminated by their fluorescence lifetimes
(Supplementary Fig. 9). Altogether, these results demonstrate that
Apo-15 is a generic marker of apoptotic cells under different
physiological environments and compatible with multiple biolo-
gical studies.
Apo-15 rapidly binds PS for real-time and wash-free imaging.
In view of the specific labeling of apoptotic cells by Apo-15, we
examined whether the amphipathic nature of Apo-15 conferred
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binding to negatively-charged phospholipids (e.g., containing PS-
headgroups) that are exposed on the plasma membrane of
apoptotic cells but are inaccessible in most viable cells. We used
giant unilamellar vesicles (GUVs, 1–10 μm) composed of neutral
phospholipids (containing only phosphatidylcholine (PC)-head-
groups, 0.2 mM) or mixed with negatively-charged PS-phospho-
lipids (PC: 0.14 mM, PS: 0.06 mM). Using fluorescence
microscopy, we observed that Apo-15 stained PC:PS GUVs with
brighter intensity than PC GUVs of similar size (Fig. 3a, b).
Binding to PS in PC:PS GUVs was confirmed by co-staining with
the positive control AF647-Annexin V in 2mM CaCl2. On the
other hand, we did not observe significant differences in fluores-
cence intensity between PC:PS GUVs and PC GUVs when stained
with the lipid marker Lissamine-Rhodamine DOPE. Furthermore,
we analyzed the specificity of Apo-15 for PS over other phos-
pholipids [i.e., cardiolipin, PC, phosphatidylglycine, phosphati-
dylethanolamine (PE)] and also phosphatidic acid. Apo-15
exhibited dose-dependent and significantly stronger binding to PS
(Fig. 3b and Supplementary Fig. 10) and showed preferential
binding to PS over PE, which is also known to localize on the
outer leaflet of the plasma membrane following induction of
apoptosis26. Apo-15 proved compatible with anisotropy readings,
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showing concentration-dependent fluorescence polarization in PS-
containing liposomes due to the environmentally-sensitive nature
of Trp-BODIPY (Supplementary Fig. 11).
Next, we examined whether Apo-15 could bind PS in cell
membranes. First, we performed competitive assays between
AF647-Annexin V and Apo-15 at different concentrations in co-
cultures of viable and apoptotic cells. We observed that high
concentrations of AF647-Annexin V could reduce binding of
Apo-15 to apoptotic cells (Fig. 3c) and also that Apo-15 reduced
Annexin V binding (Supplementary Fig. 12), suggesting that
Annexin V and Apo-15 compete for binding sites on the surface
of apoptotic cells. Secondly, we used a human cell line (i.e., PLB-
985) that is unable to translocate phospholipids to the outer
leaflet of the plasma membrane during apoptosis due to lack of
scramblase Xkr827. As a control, we used human BL-2 cells,
which expose PS on their membrane upon induction of apoptosis.
Apoptosis in both PLB-985 and BL-2 cells was induced by
treatment with staurosporine, followed by incubation with Apo-
15 and flow cytometry analysis. Apo-15 stained around 40% of
BL-2 cells, which were also stained with AF647-Annexin V,
confirming that they were apoptotic (Fig. 3d). In contrast, only
1% of PLB-985 cells were Apo-15-positive under the same
experimental conditions (Fig. 3d). We corroborated that the
treatment with staurosporine induced apoptosis in PLB-985 cells
by detection of cleaved caspase-3/7 (Supplementary Fig. 13)28,29.
Taken together, these results indicate that the selective binding of
Apo-15 occurs at early stages of apoptosis when PS is
translocated to the outer leaflet of apoptotic cells.
Given the rapid binding and fluorogenic properties of Apo-15,
we evaluated its application for real-time imaging of cells actively
undergoing apoptosis. BL-2 cells were induced to apoptosis by
exposure to UV light and treated with Apo-15 just before time-
lapse movies were acquired under wash-free conditions in a live-
cell spinning-disk microscope. We observed minimal background
fluorescence suggesting that the Apo-15 is compatible with wash-
free imaging with similar signal-to-noise ratios to annexin-based
reagents (Supplementary Fig. 14). We also observed cells that
transitioned from being non-fluorescent (i.e., viable) to Apo-15-
labeled (i.e., apoptotic), confirmed by simultaneous staining with
AF647-Annexin V (Fig. 3e and Supplementary Movies 1 and 2).
Furthermore, time-lapse quantification of the fluorescence
intensity in multiple transitioning cells demonstrated that Apo-
15 bound rapidly to apoptotic cells, with more than 90% of the
association occurring in <10 min (Fig. 3f). Next, we exploited
these features of Apo-15 to non-invasively image the dynamics of
formation of apoptotic bodies and vesicles, which have a critical
role in intercellular communication30, and are difficult to image
with annexins due to the formation of two-dimensional crystal
lattices that alter membrane dynamics31. Time-lapse imaging
following induction of apoptosis in the presence of Apo-15
revealed rapid release (<10 min) of subcellular vesicles and, in
some cases, reintegration of vesicles back into the plasma
membrane (Fig. 3g and Supplementary Movie 3). These results
confirm the utility of Apo-15 for wash-free imaging of early
apoptotic events at both cellular and subcellular levels.
Apo-15 enables imaging of apoptotic cell clearance. Functional
neutrality is an essential requirement for probes that enable
imaging of biological processes under live-cell conditions. First,
we tested whether Apo-15 affected the rate at which apoptosis
occurs in vitro. For these experiments, we cultured human neu-
trophils in the presence of different concentrations of Apo-15 and
examined the extent of tissue culture-induced apoptosis at dif-
ferent timepoints. Even when used at higher concentrations than
those required for imaging or flow cytometry, Apo-15 did not
affect the detection or the quantification of apoptosis, as mea-
sured by staining with AF647-Annexin V (Fig. 4a).
One potential limitation to the use of annexins for imaging
apoptosis is their interference with the clearance of apoptotic cells
by phagocytes. This is important for in vivo imaging studies, since
the perturbation of apoptotic cell clearance could result in over- or
under-estimation of the extent of apoptosis within a tissue. We
examined whether Apo-15 affected the engulfment of apoptotic
cells using a well-established in vitro assay to quantify the extent of
phagocytosis in human monocyte-derived macrophages (MDMs)
in the presence of the PS-opsonin protein S (Fig. 4b)32,33. Unlike
Annexin V, which significantly reduces (~50%) the phagocytic
capacity of MDMs, Apo-15 did not inhibit the phagocytosis of
apoptotic cells, even when it was used at high concentrations
(Fig. 4c). These observations were further corroborated by
fluorescence microscopy assays in co-cultures of human MDMs
and apoptotic neutrophils, where we clearly observed engulfment
of Apo-15-labeled apoptotic cells and retention of Apo-15 staining
after phagocytosis (Fig. 4d). This result opens the possibility of
using Apo-15 as a probe for tracking phagocytosis under live-cell
conditions.
Apo-15 detects drug-induced apoptosis in mouse models.
Preclinical and clinical studies have shown that low levels of free
Ca2+ are common in disease22, with many studies (e.g., intravital
imaging, in vivo therapy evaluation) being hampered by the lack
of specific apoptosis reagents that are effective in those physio-
logical environments. Given the rapid, specific and divalent
Fig. 3 Apo-15 rapidly binds exposed PS on the surface of apoptotic cells. a Fluorescence microscope images (three independent images from two
independent experiments) of GUVs with differential lipid content (PC and PC:PS). Vesicles were stained with 0.3 mol% Lissamine-Rho-DOPE (blue),
Apo-15 (100 nM, green) and AF647-Annexin V (5 nM, red) (λexc.: 488, 561, 633 nm: λem.: 525, 593, >650 nm). Scale bar: 10 µm. b Binding specificity of
Apo-15 upon incubation with different phospholipids (PS: phosphatidylserine, PG: phosphatidylglycine, PE: phosphatidylethanolamine, CL: cardiolipin, PA:
phosphatidic acid, PC: phosphatidylcholine). Data acquired on a spectrophotometer (λexc.: 450 nm, λem.: 520 nm, n > 10, except for PA) and presented as
mean values ± SEM. c Representative histograms showing Apo-15 (100 nM) labeling of mixed populations of viable and apoptotic neutrophils upon
competition with increasing concentrations of AF647-Annexin V, together with quantification of the mean fluorescence intensity of Apo-15-stained
apoptotic cells (n≥ 3) presented as mean values ± SEM. d Representative histograms of BL-2 and PLB-985 cells after treatment with staurosporine (1 µM
for 3 h) and staining with AF647-Annexin V and Apo-15 (n= 3). Apo-15-stained cells are highlighted as green dots and Apo-15-negative cells are
highlighted as black dots. Gating strategy in Supplementary Fig. 7. e Time-lapse fluorescence snapshots (from three independent experiments) of apoptotic
BL-2 cells after UV irradiation (300mJ cm−2) (Supplementary Movies 1 and 2). BL-2 cells were treated with Apo-15 (green) and AF647-Annexin V (red)
and imaged every 30 s for 15 min without washing. Arrows point at a cell when viable (white) and when undergoing apoptosis (yellow). Scale bar: 10 µm.
f Quantification of Apo-15 fluorescence intensity and presented as mean values ± SEM over time from Supplementary Movie 1 (n= 3 independent
measurements). g Time-lapse fluorescence images (from five independent cells) of subcellular apoptotic bodies (white arrow) in apoptotic neutrophils
stained with Apo-15 (green). Images were acquired every 1 s for 15 min (Supplementary Movie 3). Scale bar: 2 µm. For (b) and (c), P values were obtained
from two-tailed t tests. Source data (in b, c, and f) are provided as a Source data file.
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cation-independent binding of Apo-15, together with its wash-
free capabilities and functional neutrality, we examined whether
Apo-15 could be used for imaging of apoptotic cells in vivo in a
mouse model of ALI. This model allows temporal control
of neutrophil recruitment by intratracheal administration of
lipopolysaccharide (LPS), which is followed by neutrophil apop-
tosis and subsequent clearance by phagocytic macrophages34.
Importantly, this is a preclinical model in which the extent of
apoptosis can be modulated by cyclin-dependent kinase inhibi-
tors (CDKi)35. CDKi have profound effects on inflammatory cells
and some are under development as anticancer therapies36,37.
First, we confirmed that Apo-15 could detect CDKi-induced
apoptosis in vitro. Neutrophils incubated with the CDKi R-
roscovitine exhibited increased apoptosis by flow cytometry (as
defined by Annexin V-positive staining) with a concomitant
increase in the proportion of Apo-15 stained cells (Fig. 5a). Apo-
15 staining of CDKi-induced apoptosis was also caspase-
dependent as confirmed by a significant reduction in the
fluorescent signal after treatment with the caspase inhibitor
QVD34 (Fig. 5a). Next, we induced ALI in vivo in mice by
intratracheal administration of E. coli-derived LPS (1 μg per
mouse), and the apoptotic load in the lungs relative to saline
control was increased by intraperitoneal administration of CDKi
AT751938 (Fig. 5b). In all mice, we administered Apo-15 in vivo
and, 30 min later, we collected bronchoalveolar lavage fluid
(BALF) together with lung tissues. BALF and lung slices from
LPS-only and LPS+CDKi mice were analyzed by multipara-
meter flow cytometry to determine the proportion of apoptotic
cells that had been stained by Apo-15 in vivo (gating strategy in
Supplementary Fig. 15). Notably, a proportion of CD45+ Ly6G+
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Fig. 4 Apo-15 does not interfere with the phagocytosis of apoptotic cells. a Percentages of human neutrophils undergoing apoptosis, as indicated by
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c Flow cytometric quantification of phagocytosis of pHrodoTM-labeled neutrophils by human MDMs. Human MDMs and neutrophils were co-cultured in
the absence or presence of protein S (25 nM) and Apo-15 (60 or 600 nM) or AF647-Annexin V (25 nM). Data presented as mean values ± SEM (n≥ 3).
d Representative brightfield and fluorescence microscope images (from four independent experiments) of Apo-15-treated human neutrophils (green) in
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neutrophils in BALF were stained with Apo-15 (Fig. 5d).
Furthermore, we quantified the effects of CDKi-induced apop-
tosis in vivo by measuring the percentages of apoptotic
neutrophils in total cell counts. BALFs from LPS+ CDKi-treated
mice showed a significantly larger population of Apo-15-labeled
cells than BALFs from LPS-treated mice (29% vs. 5%, Fig. 5d).
We confirmed that CD45+ Ly6G+ cells labeled by Apo-15
in vivo were apoptotic by co-staining with AF647-Annexin V
ex vivo (Fig. 5d). Next, we acquired fluorescence microscopy
images of lung tissue sections from mice under different regimes
(Fig. 5c, e). We observed increased numbers of Apo-15-positive
cells in lungs from LPS+CDKi-treated mice when compared
with lungs of LPS-treated mice (90 vs 32 cells per μm2 tissue,
Fig. 5c) and with lungs from mice that had not been treated with
Apo-15 (Supplementary Figs. 16 and 17). Notably, the signal of
Apo-15-labeled cells was stable following processing with 10%
formalin, suggesting compatibility with fixed tissue samples.
Furthermore, flow cytometric analysis demonstrated that Apo-15
could stain CD45+CD11c+Annexin V− phagocytic macro-
phages in vivo (gating in Supplementary Fig. 15 and results in
Supplementary Fig. 18). Since viable macrophages were not
stained when BALFs were incubated with Apo-15 ex vivo
(Supplementary Fig. 18), we suggest that these macrophages
acquire fluorescence because of internalization of Apo-15-labeled
cells, further highlighting the potential utility of Apo-15 for the
identification of cell populations that have phagocytosed
apoptotic cells.
We used Apo-15 for intravital imaging of mice undergoing
ALI using optical windows providing direct access to lungs in
living mice39. Following direct intratracheal administration of
Apo-15, we performed fluorescence imaging in vivo to compare
the signals in the lungs of healthy and ALI mice. In healthy,
saline-injected control mice, we observed negligible Apo-15
staining whereas we observed bright stable staining in the lungs of
mice undergoing ALI (Fig. 5f). Furthermore, we examined the
staining of Apo-15 following drug-induced apoptosis in the
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100 µm. f Low-magnification intravital images of lungs of saline-treated and LPS-treated mice (LPS: 20 μg mL−1). Apo-15 was administered in vivo (5 μM,
green) and nuclei were counterstained with DAPI (18 μM, blue) (λexc.: 405, 488 nm; λem.: 450, 525 nm). Representative pictures from n= 3 per group.
Scale bar: 50 μm. g High-magnification fluorescence images (from three independent experiments) of tumors from xenograft breast cancer mouse models
after treatment with cisplatin (10 μg g−1). Apo-15 was administered i.v. (5 μM, green) and nuclei were counterstained with DAPI (10 μM, blue) (λexc.: 405,
488 nm; λem.: 450, 525 nm). Apoptotic cells were stained with anti-active caspase-3 (300 ngmL−1, yellow). Scale bar: 50 μm. For (a), (c), and (d), p values
were obtained from two-tailed t tests. Source data (in a, c, and d) provided as a Source data file.
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widely used MMTV-PyMT breast cancer mouse model, which
spontaneously develops tumors in the mammary glands. After
tumors were grown to a size between 0.5 and 1 cm, mice were
treated with cisplatin (10 μg g−1) to induce apoptosis and Apo-15
was injected in vivo intravenously via tail vein. As shown in
Fig. 5g, the signal of Apo-15 was retained in tumor tissues after
OCT embedding and sectioning, which allowed us to compare its
localization with that of active caspase-3. These results confirmed
that Apo-15 can label apoptotic cells in vivo as defined by activity
of caspase-3, and that it can be administered in vivo via different
routes and under various experimental conditions.
Discussion
Dysregulation of apoptosis is a defining feature of the progression
of inflammatory diseases and of cancer. Although a number of
probes for the detection of apoptosis using non-optical imaging
modalities (e.g., positron emission tomography, single-photon
emission computed tomography) have been described40,41, there
are very few optical probes that can be used in vivo (Table 1). In
particular, chemical degradation in an inflammatory micro-
environment (e.g., protease or oxidative), dependence on in vivo
availability of high concentrations of free divalent cations and
perturbation of cellular functions represent key limitations.
We have rationally designed and synthesized fluorogenic
heptapeptides that specifically overcome these limitations,
allowing us to identify a highly stable optical imaging reagent for
apoptotic cells (termed Apo-15). The functional neutrality of
Apo-15, together with the characterization of its binding to
apoptotic cells in vitro and in vivo, suggests that Apo-15 can be
used for non-invasive imaging of apoptosis in a broad range of
experimental settings, including different preclinical mouse
models.
First, we have established a solid-phase synthetic method for the
production of apopeptides (including Apo-15) as low molecular
weight (~1 kDa) fluorogenic agents for the detection of PS, widely
regarded as an early biomarker of apoptosis. Apo-15 is shorter
than other peptides reported to bind phospholipids related to
apoptosis (e.g., PE-binding duramycin and PS-binding PSBP-6 are
19-mer and 14-mer peptides, respectively)40. Furthermore, Apo-15
incorporates Trp-BODIPY as an environmentally-sensitive repor-
ter for exclusive emission in proximity to cellular membranes with
enhanced brightness over other fluorophores (Table 1). Apo-15
can be produced cost-effectively and in large scale (>100 mgs/
batch, which would allow ~300,000 in vivo imaging assays). In
contrast, PS-binding proteins like annexins (~36 kDa) or the Ca2+-
independent lactadherin C2 (~17 kDa) are difficult to manufacture
with site-specific chemical tags in large scale. The small size and
peptidic nature of Apo-15 might also favor better clearance and
biodistribution to tissues where proteins (e.g., annexins) cannot
gain access. For example, Apo-15 shares structural similarities (e.g.,
cyclic core, positively-charged amino acids) with recently devel-
oped blood brain barrier shuttle peptides42,43, suggesting that Apo-
15 or slightly modified derivatives could enable optical detection of
apoptotic cells in the brain.
Second, we have demonstrated that Apo-15 binds rapidly to
aminophospholipids, with a strong preference for PS over other
phospholipids. Of note, Apo-15 binds more strongly to PS than
PE. This observation suggests that the binding to PS may be
favored by electrostatic interactions between the positively-
charged residues (i.e., arginine, lysine) of Apo-15 and the free
negatively-charged carboxylate groups in PS, which are not pre-
sent in PE. We also showed that Apo-15 binds to cells from
different species and lineages undergoing tissue culture-induced
apoptosis as well as chemical or UV-induced apoptosis (Fig. 2).
Interestingly, although our data demonstrate that Annexin V and
Apo-15 cross-compete for binding (Fig. 3), fluorescence analysis
reveals that dual labeling with these two probes is not strictly co-
linear. One possibility is that there are differences in lipid spe-
cificity between Annexin V and Apo-15. Alternatively, the
assembly of Annexin V multimers on the apoptotic cell mem-
brane31 may restrict accessibility to the lipids. Detection of
membrane lipids offers key advantages (e.g., no need for fixatives)
over optical agents visualizing other events (i.e., caspase activa-
tion, mitochondrial dysfunction or loss of membrane integrity;
Table 1) and allows identification of apoptotic cells at early stages
of disease where therapeutic interventions may exert beneficial
effects.
Third, the divalent cation-independence of Apo-15 binding
enables in vivo detection and quantification of apoptosis in tissues
(e.g., lungs, Fig. 5) where low and/or variable levels of free Ca2+
could limit the performance of annexin-based reagents. Apo-15 is
also compatible with in vitro experimental conditions where the
use of annexins would be challenging, such as assays where cal-
cium ion concentrations need to be tightly controlled due to
potential activation of cells (e.g., the binding of platelets to
fibrinogen is highly dependent on the concentration of extra-
cellular free calcium)44. In addition, the enhanced fluorescence
emission of Apo-15 upon binding allows time-lapse imaging of
apoptosis progression in situ (Supplementary Movie 1) without
the need for washing and without significant loss of signal over
time. We have exploited these characteristics to visualize the
different stages in the formation and reabsorption of apoptotic
bodies, which will provide insights into the functions that these
structures play in different diseases (Fig. 3g and Supplementary
Movie 3).
Fourth, we have demonstrated that Apo-15 is a highly stable
peptide, even under proteolytic or oxidative conditions (Fig. 1),
overcoming an important limitation of protein-based agents. The
low molecular weight of Apo-15 (~27-fold smaller than annexins)
may allow increased tissue penetration and biodistribution
in vivo. This feature could also enable imaging studies in
optically-transparent organisms that are well-established for
developmental studies (e.g., zebrafish (D. rerio), worms (C. ele-
gans), flies (D. melanogaster)), given that apoptosis is crucial for
the appropriate formation of organs and structures during
embryonic development45. We have also demonstrated that the
staining capabilities of Apo-15 are compatible with different
administration routes. Apo-15 could facilitate mechanistic and
efficacy studies of drugs in tissues undergoing repair and/or
regeneration (e.g., liver). There is experimental evidence that the
first phases of liver injury are characterized by hepatocyte
apoptosis, which is profibrogenic46. With drugs modulating
apoptosis currently being tested for the treatment of liver injury,
the repeated in vivo administration of Apo-15—which may be
prohibitive in the case of annexins due to its cost—could repre-
sent a powerful method for longitudinal monitoring of hepatocyte
apoptosis in the liver using abdominal intravital imaging
windows47.
Finally, we and others have previously shown that promotion
or inhibition of apoptosis affects the progression and resolution
of inflammation48. In this work, we have demonstrated that Apo-
15 does not accelerate or delay apoptosis, a critical requirement
for quantitative assessment of cell death in vivo. In contrast to
annexins and lactadherin C2 proteins33,49, Apo-15 does not
inhibit the phagocytic removal of apoptotic cells by macrophages
(Fig. 4), and therefore represents a valuable tool for imaging
assays where phagocytosis and cell clearance must remain unaf-
fected. This functional neutrality of Apo-15 may enable tracking
of the ultimate fate of apoptotic material in mice. Further studies
(we were unable to co-stain ex vivo samples with Apo-15 and
antibodies given that processing and antigen retrieval methods
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17772-7
10 NATURE COMMUNICATIONS |         (2020) 11:4027 | https://doi.org/10.1038/s41467-020-17772-7 | www.nature.com/naturecommunications
results in marked loss of the Apo-15 signal) are required to
investigate whether pulses of Apo-15-labeled apoptotic cells
could be followed in vivo. Also, further studies would be required
to determine the cell types that are preferentially labeled in vivo
and the longevity of the Apo-15 fluorescence signal, particularly
when internalized apoptotic material reaches the acidic phago-
lysosome. Given experimental evidence that links dysfunctional
phagocytosis with worsening of pulmonary diseases (e.g., COPD,
cystic fibrosis)50, Apo-15 could open avenues for imaging of
apoptosis in other preclinical models and in clinical specimens.
Accumulation of apoptotic cells has been also reported in
atherosclerotic lesions, where defective phagocytic clearance can
contribute to the establishment of a pro-inflammatory necrotic
core and disease progression51. In vivo imaging of apoptosis in
these lesions, now generally done via positron emission tomo-
graphy (PET), could allow the identification of at risk vulnerable
plaques with pro-thrombotic potential52. The Trp-BODIPY in
Apo-15 contains two 19F fluorine atoms which can be isotopically
exchanged with radioactive 18F to prepare radiolabeled Apo-15
analogs for multimodal imaging (i.e., PET and optical imaging)53.
This approach could help to identify vulnerable plaques in vivo
and ex vivo using a single molecular agent, and also allow us to
test the efficacy of therapies promoting efferocytosis and reducing
apoptotic cell burden within atherosclerotic lesions.
In summary, our studies validate Apo-15 as a reliable fluoro-
genic peptide for the detection and quantification of apoptosis,
both in vitro in multiple cell lineages and in vivo in different
preclinical mouse models of inflammation and cancer. The spe-
cificity and non-invasiveness of Apo-15 could allow imaging of
apoptotic events that are not possible with current probes, from
tracking of apoptotic bodies with subcellular resolution to per-
forming intravital imaging using optical windows. Moreover,
Apo-15 labeling provides a simple and effective readout to
directly assess the efficacy of therapeutic interventions targeting
apoptosis in vivo.
Methods
Chemical synthesis and characterization. The synthesis and analytical char-
acterization data for apopeptides is described in the Supporting Information
(Supplementary Tables 1-2 and Supplementary Methods).
Cell culture and in vitro induction of apoptosis. Work with human peripheral
blood leukocytes complied with all relevant ethical regulations and informed
consent was obtained. The study protocol was approved by the Accredited Medical
Regional Ethics Committee (AMREC, reference number 15-HV-013) at the Uni-
versity of Edinburgh. Human blood leukocytes were isolated from healthy volun-
teers54. Briefly, whole blood was anti-coagulated with sodium citrate [0.4% (w/v)
final concentration] and centrifuged at 350 × g for 20 min. Platelet-rich plasma was
removed and autologous serum was generated by recalcification with CaCl2
(20 mM final concentration). Erythrocytes were separated from leukocytes by
sedimentation with Dextran T500 (0.6%) for 30 min and leukocyte populations
were further fractionated using isotonic Percoll (GE Healthcare) 49.5%/63%/72.9%
discontinuous gradients. Polymorphonuclear cells (>95% neutrophils) were har-
vested from the 63%/72.9% interface. Neutrophil apoptosis was induced by in vitro
culture for 18 h at 37 °C and 5% CO2 in IMDM supplemented with 5% autologous
serum. Monocytes were enriched from the mononuclear cells (49.5%/63% inter-
face) by negative selection using the Pan Monocyte Isolation Kit (Milentyi Biotech)
according to the manufacturer’s instructions. Monocytes were cultured for 6 days
in IMDM supplemented with 5% autologous serum to yield monocyte-derived
macrophages (MDMs).
For work with human cell lines, BL-2 and PLB-985 cells were cultured in RPMI
supplemented with 10% FBS, 100 UmL−1 penicillin and 100 µg mL−1
streptomycin. Cells were plated on 8-well confocal chambers (1.25 × 105 cells/well)
the day before imaging experiments. Apoptosis was induced by UV treatment
(300 mJ cm−2 with intervals of 6 × 50 mJ cm−2 every 30 s in BL-2 cells) or by
chemical treatment (staurosporine 1 µM for 3 h in BL-2 and PLB-985;
staurosporine 1 µM for 6 h in primary airway epithelial cells).
Primary Small Airway Epithelial cells (HSAEC) were cultured in airway
epithelial cell basal media supplemented with Bronchial Epithelial Growth Kit.
Cells were plated on 8-well confocal chamber (5 × 104 cells/well) the day before
imaging experiments. For flow cytometry experiments, cells were detached using
0.05% trypsin-EDTA for 3 min at 37 ˚C and resuspended in HEPES-NaCl buffer
containing 0.1% BSA and 2mM CaCl2 or 2.5 mM EDTA.
Mouse bone marrow-derived neutrophils were purified from C57Bl/6 mice
using discontinuous Percoll gradients as previously described55. The purity of the
neutrophil population was determined as 75–80% by analysis of cytocentrifuge
preparations. Neutrophils were induced to undergo tissue culture-induced
apoptosis by culturing for 18 h at 37 °C and 5% CO2 in IMDM with 10% FBS.
Flow cytometry and fluorescence-activated cell sorting. All apopeptides were
reconstituted at 5 mM in DMSO. Peptides were used at 100 nM in HEPES-NaCl
buffer containing 2 mM CaCl2, with or without 2.5 mM EDTA, and were incubated
with the cells for 10 min at r.t. before flow cytometry analysis, unless otherwise
stated. For co-labeling experiments, AF647-Annexin V and PI were used at the
indicated concentrations, with AF647-Annexin V being added to cells 10 min prior
to analysis and propidium iodide being added directly before analysis. BALF
analysis: 106 cells were stained for 30 min on ice with anti-mCD45-PE, anti-
mLy6G-PerCpCy5.5, and anti-mCD11c-Pacific Blue diluted 1:100 in HEPES-NaCl
buffer. After washing, AF647-Annexin V was added at 25 nM in HEPES-NaCl
buffer containing 2 mM CaCl2 for 15 min prior to acquisition. Fluorescence
emission was measured on a 5 L LSR flow cytometer (BD). Excitation sources/
emission filters used: apopeptides (488 nm/525 nm); AF647-Annexin V (641 nm/
670 nm); PI (560 nm/600 nm), anti-mCD45-PE (560 nm/580 nm), anti-mLy6G-
PerCP-Cy5.5 (488 nm/700 nm), anti-mCD11c-Pacific Blue (405 nm/450 nm). Cells
were sorted on the FACS Aria (BD), and data were analyzed with FlowJo software.
Time-lapse microscopy and live-cell imaging. Time-lapse microscopy of apop-
tosis in BL-2 cells was performed using a spinning disk confocal microscope
(Andor) equipped with a live-cell incubation system (37 °C, 5% CO2). Live-cell
imaging of different lineages was performed on a confocal laser scanning micro-
scope TCS SP8 (Leica) at 37 °C and 5% CO2. Prior to imaging, freshly isolated
neutrophils were incubated for 3 h at 37 °C in phenol red-free IMDM (Gibco)
supplemented with 2.5% autologous serum and 20 µM R-roscovitine (Sell-
eckchem). UV-treated BL-2 cells were incubated for 3 h at 37 °C prior to imaging.
AF647-Annexin V and Hoechst 33342 were used as counterstains at the indicated
concentrations. Apopeptide staining was performed by direct addition of apo-
peptides at 100 nM and imaged after 10 min. Images were processed with ImageJ
software.
Signal-to-noise ratios for apoptotic neutrophils labeled with FITC-Annexin V
or Apo-15 were determined after image acquisition under the same laser power
and gain and analysis using ImageJ. Briefly, raw images were converted into 16-bit
grayscale images and average fluorescence intensities in labeled cells and in the
background were measured (≥150 points per condition). Experiments were
performed in triplicate.
Liposome-based assays. Giant unilamellar vesicles (GUV) were prepared by the
electroformation method56. Briefly, stock solutions of lipids (0.2 mM total lipid
containing 0.3 mol% Lissamine-Rho-DOPE) were prepared in CHCl3:MeOH (2:1,
v/v) and deposited on Pt wires that were placed under vacuum for 2 h to com-
pletely remove the organic solvents. 500 µL assay buffer (25 mM HEPES, 150 mM
NaCl, pH 7.4) pre-warmed at 37 °C was then added to the chamber, and the Pt
wires were connected to a TG330 function generator (Thurlby Thandar Instru-
ments), with the field being applied in three steps at 37 °C: (1) frequency 500 Hz,
amplitude 260 mV (29 Vm−1) for 6 min; (2) frequency 500 Hz, amplitude 3.1 V
(320 Vm−1) for 20 min; (3) frequency 500 Hz, amplitude 7.3 V (656 Vm−1) for
90 min. GUVs were visualized under an inverted confocal fluorescence microscope
(Nikon D-ECLIPSE C1) with the following excitation wavelengths: 488 nm for
Apo-15, 561 nm for Lissamine-Rho-DOPE, and 637 nm for AF647-Annexin V.
Images were collected using band-pass filters (515 ± 15 nm for Apo-15, 593 ±
20 nm for Lissamine-Rho-DOPE), and a long-pass filter >650 nm for AF647-
Annexin V. For AF647-Annexin V staining, buffer containing 25 mM HEPES,
150 mM NaCl, 2 mM CaCl2, and 0.1% BSA was used. Polarized fluorescence
emission was measured in a fluorimeter plate reader PHERAstar (BMG) containing
polarizers and filters with excitation at 485 nm and emission at 520 nm.
Binding of Apo-15 to phospholipids. Cardiolipidin, PG, and PA were purchased
from Stratech Scientific Ltd. PS and PC were obtained from Sigma-Aldrich and
PE was purchased from Cambridge Biosciences. All lipids were dissolved at
1 mgmL−1 in dry EtOH and transferred into a black flat-bottom 96-well plate to
generate lipid thin layers by solvent evaporation at r.t. Apo-15 was reconstituted at
1 µM in sterile PBS and incubated at 25 °C for 40 min. Fluorescence emission was
measured in a Synergy H1 BioTek spectrophotometer (λexc.: 450 nm, λexc.: 520 nm).
All experiments were performed in triplicate.
Competition binding assays between Apo-15 and AF647-Annexin V. Neu-
trophils which had been induced to undergo tissue culture-induced apoptosis
(cultured for 18 h at 37 °C and 5% CO2 in IMDM supplemented with 5% auto-
logous serum) were pre-incubated for 10 min with different concentrations of
AF647-Annexin V or Apo-15 (as indicated in Fig. 3 and Supplementary Fig. 12) in
HEPES-NaCl buffer containing 0.1% BSA and 2mM CaCl2. Pre-incubation was
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followed by addition of AF647-Annexin V or Apo-15 at the indicated con-
centrations in HEPES-NaCl buffer containing 0.1% BSA and 2mM CaCl2. His-
tograms and mean fluorescence intensities of apoptotic cells were measured on a
5L LSR flow cytometer under the following excitation/emission filters: Apo-15
(488 nm/525 nm), AF647-Annexin V (641 nm/670 nm). Data were acquired using
the FACS Diva software and analyzed using the FlowJo X software.
Phagocytosis assays. To ensure protein-free conditions in the phagocytosis assay,
cells were washed with Hank’s balanced salt solution without Ca2+ or Mg2+
containing 2.5 mM EDTA. Prior to the phagocytosis assay, aged neutrophils (18 h
culture at 37 °C) were labeled with pHrodoTM Red SE (ThermoFisher). To examine
uptake of apoptotic neutrophils in the presence and absence of PS opsonins, the
serum component, protein S (Enzyme Research Labs) was added to a final con-
centration of 25 nM. MDMs were then co-incubated for 40 min with apoptotic
neutrophils at 37 °C at a phagocyte:target ratio of 1:6. Non-ingested apoptotic
neutrophils were removed by aspiration and cells were detached with 0.05%
trypsin-EDTA for 5 min at 37 °C followed by incubation on ice. The percentages of
fluorescent MDMs (i.e., those that had ingested apoptotic cells) were determined
on the 5L LSR (BD Bioscience). For imaging, MDM were cultured on 9-mm-
diameter round glass coverslips (ThermoFisher) and mounted with ProLong gold
(ThermoFisher) on microscope slides. Images were taken on a LSM 510 Zeiss
confocal microscope.
In vivo monitoring of apoptosis in a model of lung inflammation. Animal testing
and research complied with all relevant ethical regulations. The study protocol was
approved by the UK Home Office at the University of Edinburgh and by the Uni-
versity of Edinburgh animal welfare Committee (Project License: PPL 60/4502). Mice
were housed in a specific-pathogen-free facility with standard husbandry. In a mouse
model of acute lung inflammation34, 8–12-week-old C57BL/6 mice were adminis-
tered intratracheally E. coli-derived (O127:B8) LPS (20 µgmL−1, 50 µL sterile saline
per mouse), combined S. aureus-derived LTA (150mg) and PepG (50mg). Dark and
light cycles were 12 h. After 18 h, mice received either 30mg kg−1 AT7519 intra-
peritoneally in 200 µL sterile saline or 200 µL of vehicle control. At 36 h post-LPS
instillation, 5 µM Apo-15 in 50 µL sterile saline was administered, and lavages and
lung tissue were harvested 30min later. Lungs were lavaged with three aliquots of
800 µL sterile ice-cold saline. Bronchoalveolar lavage fluid (BALF) was centrifuged at
300 × g for 5 min and BALF cells were analyzed for flow cytometry and Diff-Quick
staining. Lungs for histological analysis were perfused with saline followed by fixation
with 10% formalin.
Intravital imaging. Female C57BL/6 mice at 8 weeks of age were administered E.
coli-derived LPS (20 µg mL−1, 50 µL sterile saline per mouse) intratracheally or an
equal volume of saline. After 48 h, 50 µL of Apo-15 (5 µM) in saline (<0.1%
DMSO) was administered intratracheally. Mice were anesthetized by intraper-
itoneal injection of ketamine/dexdomitor (100 mg/kg/0.5 mg/kg). Saline (500 µL)
was injected peritoneal prior to surgery, tracheotomies performed, and mechanical
ventilation (MiniVent Model 845, Harvard Apparatus) initiated with the mice on a
heated stage. Thereafter, mice were kept anesthetized at 0.8–1.0% isoflurane
delivered through the ventilator at 100 breaths per minutes with 25 mL H2O
maintaining positive end expiratory pressure. A thoracotomy was performed39.
Briefly, an incision was made between the 4th and 5th left ribs and a 3D-printed
thoracic suction window with 8-mm coverslip inserted. The window was kept in
place with single-axis translator micromanipulators (#MSH1.5 Thor Labs), and
vacuum pressure (15–20 mmHg) was applied to avoid motion artefacts of the
imaged tissue regions. At the time of imaging, 50 µL of DAPI (5 µg mL−1) was
administered intravenously and images captured for up to 1–2 h. Mice were imaged
with a custom-built spinning disk confocal microscope (Solamere Technologies)
modified to upright configuration using a LD 20X Fluar 0.4 NA lens (Zeiss
Microscopy)57. The microscope was controlled by MicroManager software and
time-lapse movies generated from the acquired images using Imaris (Bitplane)
software.
In vivo staining of cisplatin-induced apoptosis in a MMTV-PyMT breast
cancer mouse model. Animal testing and research complied with all relevant
ethical regulations. The study protocol was approved by the Institutional Animal
Care and Use Committee (IACUC) at Cold Spring Harbor Laboratories. Animal
experiments were conducted in accordance with the NIH Guide for Care and Use
of Laboratory Animals. MMTV-PyMT (C57BL/6 background) is a reported breast
cancer mouse model to spontaneously develop tumors in the mammary glands as
previously described58. Tumors were grown to a size between 0.5 and 1 cm, and
then mice were treated with cisplatin (10 μg g−1) to induce apoptosis.
Prior to administration of Apo-15, mice were anaesthetized with 4% isofluorane
and kept anesthetized under 1–2% isoflurane and 21% oxygen and balanced with
nitrogen at 1 L min−1. Mice were given Apo-15 in vivo intravenously (5 µM, total
volume 100 µL) and tumor tissues were harvested after 2 h. Tissues were fixed in
4% paraformaldehyde for 2 h, incubated in gradual increasing concentrations of
sucrose, embedded in OCT media and frozen. Tumor tissues were then sectioned,
rehydrated, and blocked with PBS containing 2.5% BSA and 20% goat serum.
Primary antibody staining was performed overnight with 1:200 rabbit anti-cleaved
caspase-3 antibody (Cell Signalling) in PBS containing 1.25% BSA and 10% goat
serum at 4 °C. Slides were then washed three times with PBS and stained with
1:400 secondary goat anti-rabbit AF647-IgG (H+ L) and DAPI (10 μM) in PBS
containing 1.25% BSA and 10% goat serum for 1 h at r.t. Slides were mounted
using ProlongGold, imaged under a Leica SP8 confocal microscope. Excitation/
emission filters used: DAPI (405 nm/450 nm), Apo-15 (488 nm/525 nm), and
AF647 (641 nm/670 nm). Images were analyzed and processed with ImageJ
software.
Statistical analysis. Statistical differences were analyzed two-sided unpaired t tests
using Graphpad software. Independent experiments were performed at least three
times, unless otherwise mentioned.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1b, 2d, 3b, c, f, 4a, c, 5a, c and d and Supplementary
Figs. 1, 4, 10, 11, 12 and 14 are provided as a Source data file. Additional data that
support findings of this study are available from the corresponding authors upon
reasonable request. Source data are provided with this paper.
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